3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1
1
Status
Completed
16
Recruiting
3
Active not recruiting
3
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
37
Breast Neoplasms
26
Prostatic Neoplasms
22
Stomach Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
12
Lung Neoplasms
11
Neoplasms
10
Urinary Bladder Neoplasms
8
Head and Neck Neoplasms
8
Triple Negative Breast Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Squamous Cell
6
Non-Muscle Invasive Bladder Neoplasms
5
Nasopharyngeal Carcinoma
5
Carcinoma, Transitional Cell
5
Adenocarcinoma
5
Oropharyngeal Neoplasms
4
Sarcoma
3
Prostatic Neoplasms, Castration-Resistant
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Metastatic Castration-resistant Prostate Cancer
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Vaccinia
2
Recurrence
2
Peritoneal Neoplasms
2
Metastatic Castration-Resistant Prostate Cancer
2
Melanoma
2
Interventions
pembrolizumab
19
Paclitaxel
13
Carboplatin
10
Pemetrexed
4
Cisplatin
4
patritumab deruxtecan
3
Gemcitabine
3
Docetaxel
3
Capecitabine
3
Albumin-Bound Paclitaxel
3
Histamine H2 Antagonists
2
Histamine Antagonists
2
Dexamethasone
2
Acetaminophen
2
130-nm albumin-bound paclitaxel
2
trastuzumab deruxtecan
1
osimertinib
1
olaparib
1
liposomal doxorubicin
1
lenvatinib
1
enzalutamide
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Serotonin 5-HT3 Receptor Antagonists
1
Ramucirumab
1
Oxaliplatin
1
Neurokinin-1 Receptor Antagonists
1
Neoadjuvant Therapy
1
Levoleucovorin
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Docetaxel
×
Clear all
NCT06952504
2026-05-22
TroFuse-033
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,123 enrolled
NCT06989112
2026-05-06
DE-01
AstraZeneca
Phase 3
Recruiting
600 enrolled
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled